Found: 1
Select item for more details and to access through your institution.
Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 4, p. 781, doi. 10.1111/dom.13574
- By:
- Publication type:
- Article